Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Decision on Stock Companies' Management of Medical Institutions Remains Unpredictable
December 23, 2002
- NEW PRODUCTS IN BRIEF
December 23, 2002
- Bill on New Drug Organization Clears the Diet
December 23, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
December 23, 2002
- No Meaningful Progress on Mutual Recognition: MOSS Follow-up Talks
December 23, 2002
- OTC NEWS IN BRIEF
December 23, 2002
- Strong Incentives Essential to Development of Innovative Drugs: CEFP
December 23, 2002
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
December 23, 2002
- REGULATORY NEWS IN BRIEF
December 23, 2002
- DIAGNOSTIC NEWS IN BRIEF
December 23, 2002
- Tracheal Intubation by Lifeguards to Be Permitted from July 2004
December 23, 2002
- EFPIA Wishes to Actively Participate in Japanese Healthcare Reform Talks
December 23, 2002
- Korosho to Classify Medical Fees into Doctors' and Hospitals' Fees
December 23, 2002
- Mevalotin's Patent Expiration Brings Sankyo No. 1 Issue
December 23, 2002
- SCN Group to Integrate Internet Services for Medical Professionals
December 23, 2002
- Fuso Extends Anticancer Gene Therapy Research Agreement with GenVec
December 23, 2002
- EPS Group Separates Its CRO and SMO Businesses
December 23, 2002
- WORLD NEWS IN BRIEF
December 23, 2002
- Banyu to Maintain Sales of Lipovas Based on Evidence from Clinical Trials
December 23, 2002
- PM Reiterates Support for Stock Companies' Management of Medical Facilities: Diet
December 23, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…